Furosemide, when used in combination with positive end-expiratory pressure, facilitates the resorption of extravascular lung water in experimental hydrostatic pulmonary oedema.
The study aimed to establish whether furosemide given intravenously improved resorption of hydrostatic pulmonary oedema in 14 dogs mechanically ventilated with positive end-expiratory pressure (PEEP). Hydrostatic pulmonary oedema was created by simultaneous inflation of a left atrial balloon and rapid intravenous infusion of isotonic saline. The hydrostatic process was terminated by deflating the balloon and reducing the infusion rate. A PEEP of 10 cmH2O (1.0 kPa) was applied in all animals; in seven, furosemide was administered (diuretic group), 1 mg/kg intravenously as a bolus followed by an infusion of 0.5 mg/kg per hour, while the remaining seven dogs served as a control group. All dogs were studied for a period of 4 h. The extravascular lung water measured with the double indicator dilution technique was 28.3 +/- 3.8 (diuretic group) and 28.2 +/- 6.8 ml/kg (control group) during maximum oedema. It was reduced to 16.4 +/- 2.2 (diuretic group) vs 19.8 +/- 3.7 ml/kg (control group) after 4 h of resorption, P less than 0.05. Postmortem gravimetric values of extravascular lung water were 9.1 +/- 3.4 (diuretic group) vs 12.6 +/- 5.0 g/kg (control group). In the diuretic group the urinary output increased threefold, and haemoglobin and serum protein concentrations were higher than in the control group. There was a significantly greater decrease in cardiac output and central blood volume in the diuretic group. In conclusion, furosemide given intravenously improved lung fluid resorption in hydrostatic pulmonary oedema, probably by increasing the plasma colloid osmotic pressure.
Wickerts
C J
CJ
Department of Anaesthesia and Intensive care, Danderyd Hospital, Sweden.
Blomqvist
H
H
Berg
B
B
Rösblad
P G
PG
Hedenstierna
G
G
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001798:Blood Proteins / Q000032:analysis; D001810:Blood Volume / Q000187:drug effects / Q000502:physiology; D002245:Carbon Dioxide / Q000378:metabolism; D002302:Cardiac Output / Q000187:drug effects; D002496:Central Venous Pressure / Q000187:drug effects / Q000502:physiology; D004285:Dogs; D015633:Extravascular Lung Water / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D008297:Male; D011175:Positive-Pressure Respiration; D011654:Pulmonary Edema / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects / Q000502:physiology
D001798:Blood Proteins; D006454:Hemoglobins; D002245:Carbon Dioxide; D005665:Furosemide